Check-Cap (CHEK) 20-F/A 7 Apr 16 2015 FY Annual report (foreign) (amended) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2015shares
Document and Entity Information [Abstract]
Document Type	20-F
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Entity Registrant Name	Check-Cap Ltd
Entity Central Index Key	1,610,590
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Common Stock, Shares Outstanding	11,811,709

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 9,392	$ 1,075
Restricted cash	46	$ 46
Short-term bank deposit	4,811
Prepaid expenses and other current assets	680	$ 117
Total current assets	14,929	1,238
Non-current assets
Property and equipment, net	$ 369	191
Deferred issuance costs		1,556
Total non-current assets	$ 369	1,747
Total assets	15,298	2,985
Accounts payable and accruals
Trade	577	333
Other	245	1,355
Other current liabilities	13	50
Employees and payroll accruals	1,238	1,122
Total current liabilities	2,073	2,860
Non-current liabilities
Royalties provision	$ 577	544
Warrants to purchase preferred shares		407
Total non-current liabilities	$ 577	951
Shareholders' equity (deficiency)
Preferred shares		226
Share capital	$ 599	53
Additional paid-in capital	46,164	20,720
Accumulated deficit	(34,115)	(21,825)
Total shareholders' equity (deficiency)	12,648	(826)
Total liabilities and shareholders' equity (deficiency)	$ 15,298	$ 2,985

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Dec. 31, 2015	Dec. 31, 2014
Preferred shares
Par value	₪ 0.2	₪ 0.2
Authorized	0	12,142,291
Issued	0	4,338,998
Outstanding	0	4,338,998
Ordinary shares
Par value	₪ 0.2	₪ 0.2
Authorized	57,500,000	45,357,710
Issued	11,811,709	1,152,138
Outstanding	11,811,709	1,152,138

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Research and development expenses, net	$ 5,837	$ 2,832	$ 2,893
General and administrative expenses	$ 6,626	$ 1,703	1,090
Other income			(11)
Operating loss	$ 12,463	$ 4,535	3,972
Financial income, net	173	3,925	604
Net loss	$ (12,290)	$ (610)	$ (3,368)
Net loss per ordinary share (in USD) basic and diluted	$ 1.06	$ 1.18	$ 3.27
Weighted average number of ordinary shares outstanding - basic and diluted (in thousands)	11,918	2,181	1,627

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) - USD ($) $ in Thousands	Total	Preferred shares [Member]	Ordinary shares [Member]	Additional paid-in capital [Member]	Accumulated deficit [Member]
Beginning balance at Dec. 31, 2012	$ 2,783	$ 226	$ 53	$ 20,351	$ (17,847)
Beginning balance, shares at Dec. 31, 2012		4,338,998	1,152,138
Share-based compensation	$ 57			$ 57
Issuance of ordinary share upon exercise of stock options by employees, shares
Net loss	$ (3,368)				$ (3,368)
Ending balance at Dec. 31, 2013	(528)	$ 226	$ 53	$ 20,408	$ (21,215)
Ending balance, shares at Dec. 31, 2013		4,338,998	1,152,138
Share-based compensation	$ 312			$ 312
Issuance of ordinary share upon exercise of stock options by employees, shares
Net loss	$ (610)				$ (610)
Ending balance at Dec. 31, 2014	(826)	$ 226	$ 53	$ 20,720	$ (21,825)
Ending balance, shares at Dec. 31, 2014		4,338,998	1,152,138
Conversion of preferred shares into ordinary shares	$ 20,197	$ (226)	$ 226
Conversion of preferred shares into ordinary shares, shares	4,338,998	(4,338,998)	4,338,998
Reclassification of liability warrants to equity warrants	$ 233			$ 233
Issuance of ordinary shares in the IPO	$ 10,751		$ 113	10,638
Issuance of ordinary shares in the IPO, shares	2,250,000		2,250,000
Issuance of ordinary shares in the Private Placement	$ 10,900		$ 101	10,799
Issuance of ordinary shares in the Private Placement, shares	2,000,000		2,000,000
Exercise of warrants into ordinary shares	$ 29		$ 90	(61)
Exercise of warrants into ordinary shares, shares			1,763,106
Share-based compensation	3,724			$ 3,724
Issuance of ordinary share upon exercise of stock options by employees	$ 16		$ 16
Issuance of ordinary share upon exercise of stock options by employees, shares	307,467		307,467
Capital investment	$ 111			$ 111
Net loss	(12,290)				$ (12,290)
Ending balance at Dec. 31, 2015	$ 12,648		$ 599	$ 46,164	$ (34,115)
Ending balance, shares at Dec. 31, 2015			11,811,709

CONSOLIDATED STATEMENTS OF CHA6

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIENCY) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Statement of Stockholders' Equity [Abstract]
Reverse stock split	0.05
Issuance expenses	$ 3,849
Value or warrants	321
IPO [Member]
Issuance expenses	2,945
Value or warrants	196
Private Placement [Member]
Issuance expenses	1,225
Value or warrants	$ 125

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (12,290)	$ (610)	$ (3,368)
Adjustments required to reconcile net loss to net cash used in operating activities:
Revaluation of fair value of warrants to purchase preferred share	(174)	(3,519)	(623)
Depreciation and amortization	92	78	77
Share-based compensation	3,724	312	56
Financial expenses (income), net	(11)	1
Changes in assets and liabilities items:
Decrease (increase) in prepaid and other current assets and non-current assets	(563)	(1,545)	514
Increase in trade accounts payable, accruals and other current liabilities	334	1,377	82
Increase in employees and payroll accruals	227	466	148
Increase (decrease) in royalties provision	33	(415)	104
Net cash used in operating activities	(8,628)	(3,855)	(3,010)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	$ (270)	$ (46)	(45)
Restricted cash			(3)
Investment in (proceeds from) short-term bank deposit	$ 4,800		(3,450)
Net cash provided by (used in) investing activities	(5,070)	$ (46)	$ 3,402
CASH FLOWS FROM FINANCING ACTIVITIES
Receipt of short-term loan from bank	1,000
Repayment of short-term loan from bank	(1,000)
Issuance of ordinary shares upon exercise of stock options by employees	16
Exercise of warrants into ordinary shares	29
Issuance of ordinary shares in the Private Placement, net of issuance expenses	11,021
Issuance of ordinary shares in IPO, net of issuance expense	10,947
Net cash provided by financing activities	22,013
Effect of exchange rate changes on cash and cash equivalents	2	$ 1
Net increase (decrease) in cash and cash equivalents	8,317	(3,900)	$ 392
Cash and cash equivalents at the beginning of the year	(1,075)	(4,975)	(4,583)
Cash and cash equivalents at the end of the year	(9,392)	$ (1,075)	$ (4,975)
Supplemental disclosure of non-cash flow information
Reclassification of liability warrants to equity warrants	233
Cashless exercise of warrants to purchase ordinary shares into ordinary shares	45
Conversion of preferred shares into ordinary shares	226
Supplemental disclosure of cash flow information
Cash paid for interest	$ 11

GENERAL INFORMATION

GENERAL INFORMATION	12 Months Ended
	Dec. 31, 2015
GENERAL INFORMATION [Abstract]
GENERAL INFORMATION	NOTE 1 - GENERAL INFORMATION A. General (1) Check Cap Ltd. (together with its wholly-owned subsidiary, the “Company") was incorporated under the laws of the state of Israel. The registered address of its offices is Abba Hushi Blvd., Isfiya. (2) Check-Cap Ltd has a wholly-owned subsidiary, Check-Cap U.S. Inc, incorporated under the laws of the United States (U.S.) on May 15, 2015. (3) The Company is a clinical stage medical diagnostics company developing the first non-invasive system for preparation-free imaging of the colon to identify precancerous polyps and cancers. The Company is developing an ingestible capsule that utilizes proprietary, ultra-low-energy X-ray-based technology to safely generate high-resolution, 3-dimensional imagery of the interior of the colon. Without requiring traditional bowel cleansing or diet and activity modifications, The Company's system is designed to increase patient acceptance and adherence to colorectal cancer screening recommendations. The Company's system is currently not cleared for marketing in any jurisdiction. (4) As described in Note 10E(2)(b), on February 24, 2015 the Company consummated an Initial Public Offering in the U.S. (the "IPO") concurrently with a Private Placement (the "Private Placement"). (5) The consolidated financial statements of the Company as of and for the year ended December 31, 2015 comprise the Company and its wholly-owned U.S. subsidiary. B. Financial Position Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company's future operating losses and the timing of becoming profitable are uncertain. The Company has incurred losses of $ 12.3 0.6 3.4 34.1 Management expects that the Company will continue to generate losses from its development and clinical activities which will result in a negative cash flow from operating activity. Management expects that the Company's existing cash will be sufficient to fund the Company's projected operating requirements for at least another 15 months following December 31, 2015. C. Reverse Share Split On January 15, 2015, the Company's shareholders approved a reverse share split of 1 for 20 (i.e. 20 ordinary shares will be combined into one ordinary share), subject to and effective immediately prior to the IPO, provided that the IPO is consummated on or prior to December 31, 2015. D. Conversion of Preferred Shares and Preferred Share Warrants On January 15, 2015, the Company's shareholders approved the conversion on a 1 1 0.01 1 1 Immediately prior to the consummation of the IPO, on February 24, 2015, 4,338,998 4,338,998 948,000 948,000

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company's consolidated financial statements are presented in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The Company recasted the comparative amounts included in this financial statements to U.S. GAAP. In prior years the Company prepared its financial reports in accordance with International Financial Reporting Standards ("IFRS"). A. Use of Estimates in Preparation of Financial Statements T B. Principles of Consolidation The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances. C. Financial statements in U.S dollars The Company has not yet generated revenues, and the majority of its expenses is in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other. Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management is using these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company. Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate. D. Cash and cash equivalents and restricted cash Cash and cash equivalents includes cash in hand and short–term deposits in banks with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value. The Company had a restricted cash balance of $ 46 E. Short-term bank deposit Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short–term bank deposits are presented at their cost, including accrued interest, which approximates fair value. As of December 31, 2015, the Company's short–term bank deposit was in dollars and bore interest rate of 0.51 F. Concentration of credit risks Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and short-term bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments. G. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is using the straight-line method over the estimated useful lives of the assets at the following annual rates: Length of useful life Depreciation rate Years % Office furniture and equipment 10 - 14 7 - 10 Laboratory equipment 3 - 7 15 - 33 Computers and auxiliary equipment 3 33 H. Impairment of Long-Lived Assets The Company's long-lived assets are reviewed for impairment in whenever events or changes in indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2015, 2014 and 2013, no impairment losses have been recorded. I. Research and development costs Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the “OCS”) and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company will generate sales from these projects and pay the royalties resulting from such sales). See Note 12 below regarding the offset of grants received for participation in research and development expenses. J. Warrants to purchase preferred shares The Company accounts for freestanding warrants to purchase its preferred shares as a liability on the balance sheets at fair value. The warrants to purchase preferred shares are recorded as a liability as they include anti-dilution protection provision requiring a reduction in original exercise price as a result of subsequent issuance below the original exercise price. The warrants are subject to re-measurement to fair value at each balance sheet date and any change in fair value is recognized as a component of financial income (expense), net, in the statements of operations. The Company must adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants, or the conversion of convertible preferred shares into ordinary shares. Immediately prior to the consummation of the Company's IPO in February 2015, all of the remaining warrants to purchase preferred shares were converted to warrants to purchase ordinary shares, without the anti-dilution protection provision and the warrants were reclassified into equity at their current fair value (see Note 9). K. Fair Value Measurement Fair value is defined as the exchange price that would be received for an asset or paid to a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows: • Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions. L. Contingent liabilities The accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of , estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2015 and 2014, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note 8). M. Share-based compensation In accordance with ASC 718-10 "Compensation-Stock Compensation" the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations. The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award, net of estimated forfeitures. ASC No. 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures. The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. Prior to the Company's IPO, the fair value of the ordinary shares underlying the share options has been determined based on recent e quity investment by the Company's Board of Directors. After the IPO and until March 18, 2015, the date the units , issued by the company in the IPO, After the Unit Separation Date, the grant date fair value for share-options awards is based on the closing price of the ordinary shares on the NASDAQ Capital Market on the date of grant and fair value for all other purposes related to share-options awards is the closing price of the Company's ordinary shares on the NASDAQ Capital Market on the relevant date. The fair value for options granted in 2015, 2014 and 2013 is estimated at the date of grant using a Black-Scholes-Merton option-pricing model with the following assumptions: December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Expected volatility 44 -62 % 50 -60 % 40 -60 % Risk-free rate 1.29 -2.28 % 1.45 -1.72 % 0.75 -2.25 % Dividend yield 0 % 0 % 0 % Expected term (in years) 4 10 5 6 5 10 Share price $ 3 5.12 $ 3.01 $ 3.04 The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model. N. Income taxes The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered ‘more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2015 and 2014, the Company had no unrecognized income tax positions and correspondingly there is no impact on the Company's effective income tax rate associated with these items. O. New Accounting Pronouncements In November, 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-17, Topic 740 - Balance Sheet Classification of Deferred Taxes. The ASU requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. Netting of deferred tax assets and deferred tax liabilities by tax jurisdiction is still required under the new guidance. The Company will apply the ASU in its future financial statements. In 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company's financial statements. In June 2014 the FASB issued Accounting Standards Update ("ASU") 2014-10 regarding development stage entities. The ASU removes the definition of development stage entity, as was previously defined under U.S. GAAP, from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders' equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments' to ASU 2014-10 are effective for annual reporting periods beginning after December 15, 2014. The Company has applied the ASU in these financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Dec. 31, 2015
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 3 - PREPAID EXPENSES AND OTHER CURRENT ASSETS Composition: December 31, 2 0 1 5 2 0 1 4 Government institutions 400 46 Prepaid expenses 197 27 Deposits 55 43 Other assets 28 1 680 117

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2015
PROPERTY AND EQUIPMENT, NET [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 4 - PROPERTY AND EQUIPMENT, NET Composition: December 31, 2 0 1 5 2 0 1 4 Cost: Office furniture and equipment 100 92 Laboratory equipment 378 306 Computers and auxiliary equipment 396 206 874 604 Accumulated depreciation 505 413 Property and equipment, net 369 191 Depreciation expenses amounted to $ 92 78 77

SHORT TERM LOANS

SHORT TERM LOANS	12 Months Ended
	Dec. 31, 2015
SHORT TERM LOANS [Abstract]
SHORT TERM LOANS	NOTE 5 - SHORT TERM LOANS On January 4, 2015, the Company entered into a credit line agreement with Bank Leumi pursuant to which it was entitled to obtain a credit line in the principal amount of up to $ 1,000 5.25 1,000 20 100

EMPLOYEE BENEFITS AND PAYROLL A

EMPLOYEE BENEFITS AND PAYROLL ACCRUALS	12 Months Ended
	Dec. 31, 2015
EMPLOYEE BENEFITS AND PAYROLL ACCRUALS [Abstract]
EMPLOYEE BENEFITS AND PAYROLL ACCRUALS	NOTE 6 - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS A. Composition: December 31, 2 0 1 5 2 0 1 4 Short-term employee benefits: Benefits for vacation and recreation pay 275 332 Liability for payroll, bonuses and wages 963 790 1,238 1,122 B. Post-employment Benefits Pursuant to Israel's Severance Pay Law, Israeli employees are entitled to severance pay equal to one month's salary for each year of employment, or a portion thereof. All of the Company's employees elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, employees are entitled only to monthly deposits, at a rate of 8.33 C. Short-term employee benefits (1) Paid vacation days In accordance with the Yearly Vacation Law-1951 (the "Vacation Law"), the Company's employees are entitled to a number of paid vacation days for each year of employment. In accordance with the Vacation Law and its appendix, and as determined in the agreement between the Company and the employees, the number of vacation days per year to which each employee is entitled is based on the seniority of the employee. The employee may use vacation days based on his or her needs and with the Company's consent, and to accrue the remainder of unused vacation days, subject to the provision of the Vacation Law. The vacation days utilized first are those credited for the current year and subsequently from any balance transferred from the prior year (on a “LIFO” basis). An employee who ceased working before utilizing the balance of vacation days accrued is entitled to payment for the balance of unutilized vacation days. (2) Related parties For information regarding short-term employee liabilities given to related parties see Note 16.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 7 - INCOME TAXES A. The Company Check-Cap Ltd. is taxed according to Israeli tax laws: 1. Corporate tax rates in Israel The Israeli corporate tax rate was 26.5 25 2. The Law for the Encouragement of Capital Investments, 1959 (the “Investments Law”) Under the Investments Law, including Amendment No. 60 to the Encouragement of Capital Investments Law as published in April 2005, by virtue of the “Approved Enterprise” or “Benefited Enterprise” status the Company is entitled to various tax benefits as follows: a) Reduced tax rates The Company has one Benefited Enterprise program under the Investments Law, which entitles it to certain tax benefits with respect to income to be derived from the Company's Benefited Enterprise. During the benefits period, taxable income from its Benefited Enterprise program (once generated) will be tax exempt for a period of ten years commencing with the year the Company will first earn taxable income relating to such enterprise. The Company chose 2010 as the year of election (the "Year of Election"). Due to the location of the Company's offices, the Company believes it is entitled to a 10 year benefit period, subject to a 14 year limitation from the Year of Election, and therefore, the tax benefit period will in any event end in 2023. b) Conditions for entitlement to the benefits The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations. c) Amendment of the Law for the Encouragement of Capital Investments, 1959 The Encouragement of Capital Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the “Capital Investments Law Amendment”). The Capital Investments Law Amendment sets alternative benefit tracks to those currently in effect under the provisions of the Encouragement of Capital Investments Law. The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set in the law; for the most part, those criteria are similar to the criteria that were set in the Encouragement of Capital Investments Law prior to its amendment. Under the transitional provisions of the Encouragement of Capital Investments Law, the Company is entitled to take advantage of the tax benefits available under the Encouragement of Capital Investments Law prior to its amendment until the end of the benefits period, as defined in the Encouragement of Capital Investments Law. The Company will be allowed to set the “year of election” no 2012 2010 3 In accordance with the Income Tax Ordinance, as of December 31, 2015, all of Check-Cap Ltd.'s tax assessments through tax year 2010 4 The Company did not record current taxes for the years ended December 31, 2013, 2014 2015 no 5 The NOL carry-forward of the Company equal to approximately $ 23.6 B. Check-Cap U.S. Inc. 1 Check-Cap U.S. Inc. is taxed according to U.S. tax laws. The Company's income is taxed in the U.S. at the rate of up to 39 2 The NOL carry-forward of Check-Cap U.S. Inc equal to approximately $ 11 C. Deferred income taxes In the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company's history of losses, the Company established a full valuation allowance. December 31, 2 0 1 5 2 0 1 4 Carry forward tax losses 23,565 16,800 Less valuation allowance (23,565 ) (16,800 ) - - D. Reconciliation of the theoretical tax expense to actual tax expense The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2015
COMMITMENTS AND CONTINGENT LIABILITIES [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 8 - COMMITMENTS AND CONTINGENT LIABILITIES A. Royalties provision 1. Royalties to an ASIC designer The Company has a liability to pay royalties for the development of an ASIC component which is used as an amplifier for the capture of signals at low frequencies from X-ray detectors contained in the capsule. The institution that developed the ASIC is entitled to a receive royalties from the Company in the amount of € 0.5 0.54) 200 218) The royalties liability is calculated based on estimated future sales generated by products which includes the ASIC component. As of December 31, 2015, the Company believes that it will be required to pay the above mentioned royalties, and accordingly, recorded, as of December 31, 2015, a provision in a total amount of $159. 2. Reimbursement liability to Predecessor Entity's unit holders On May 31, 2009, the Company entered into an asset transfer agreement with Check Cap LLC (the “Predecessor Entity”), a company with the same shareholders as the Company at the time of transfer. According to the agreement, the Predecessor Entity transferred all of its business operations substantially all of its assets to the Company, including development and consulting agreements, cash, property and equipment and intangible ownership rights, free of any debt. As part of the reorganization the Company committed to reimburse the unit holders of the Predecessor Entity for any tax burdens that may be imposed on them due to the reorganization. The reimbursement liability is calculated assuming deemed royalties are paid to the U.S. unit holders of the Predecessor Entity under Section 367(d) of the Code and is based in part on the December 31, 2 0 1 5 2 0 1 4 Royalties to an ASIC designer 159 151 Reimbursement liability to Predecessor Entity's unit holders 418 393 577 544 B. Commitments (1) Royalties The Company's research and development efforts are financed, in part, through funding from the OCS and BIRD Foundation. Since the Company's inception through December 31, 2015, the Company received funding from the OCS and BIRD Foundation in the total amount of $ 3.6 127 3 5 funded, up to the full principal amount (which may be increased under certain circumstances) of the U.S. Dollar-linked value of the grants, plus interest at the rate of 12-month LIBOR. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. As of December 31, 2015, we had a contingent obligation to the OCS in the amount of $ 3.8 On July 13, 2014, the Company entered into a Cooperation and Project Funding Agreement with the BIRD Foundation and Synergy, pursuant to which the BIRD Foundation has agreed to award a grant in the maximum amount of the lesser of (i) $ 900 50 24 According to the terms of the grant, the BIRD Foundation is entitled to royalties equal to 5 100 113 125 138 150 one 30 . As of December 31, 2015, the Company had not paid any royalties to the OCS and BIRD. (2) Rental agreement The Company leases approximately 610 square meters in Isfiya, Israel under a lease agreement providing for a term of 10 67 60 56 (3) Agreements for brokerage services See Note 10E(2)(d). (4) Vehicle Lease and Maintenance Agreements The Company entered into several 32 36 14 131 98 16 Operating lease obligations as of December 31, 2015: Lease agreement for vehicles 29 Lease agreement for office facilities lease 13 42 C. Legal As of the date of the financial statements, the Company has not been and is not a party to any pending litigation.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2015
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 9 - FAIR VALUE MEASUREMENTS Financial instruments measured at fair value on a recurring basis include warrants for preferred share. The warrants are classified as a liability in accordance with ASC No. 480 "Distinguishing Liabilities From Equity" (see Notes 10D(3) and 10D(4)). These warrants were classified as level 3 in the fair value hierarchy since some of the inputs used in the valuation were determined based on management's assumptions. The fair value of the warrants on the issuance date and on subsequent reporting dates was determined using option-pricing-model utilizing the assumptions noted below. The fair value of the underlying preferred share price was determined by the board of directors considering, among others, third party valuations. The valuation of the Company was performed using a discounted The assumptions were used to estimate the value of the warrants to purchase series C1 and C2 convertible preferred shares: February 24, 2015 (conversion date) December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Expected volatility 55.69 % 51.7 % 44 % Risk-free rate 1.21 % 1.58 % 0.13 % Dividend yield 0 % 0 % 0 % Expected term (in years) 4.17 4.20 3.42 On November 22, 2014 and January 21, 2015, 18,586 8,366 41,822 50,399 92,221 The assumptions were used to estimate the value of the warrants to purchase series D1 and D2 preferred shares: December 31, 2 0 1 4 2 0 1 3 Expected volatility 60.12 % 44 % Risk-free rate 0.05 % 0.18 % Dividend yield 0 % 0 % Expected term (in years) 0.21 1.21 On February 24, 2015 all of the warrants to purchase preferred shares were converted into warrants to purchase ordinary shares (See note 1D) and lost their anti-dilution protection provision. As a result, these warrants were converted into equity. Series D1 and D2 warrants expired on March 17, 2015. The Company's management estimated that the value of these warrants as of February 24. 2015 (conversion date) was immaterial. The change in the fair value of warrants to purchase preferred shares is summarized below: December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Balance at the beginning of year 407 3,926 4,549 Conversion to warrants to purchase ordinary share immediately prior to the IPO (233 ) - - Change in fair value (174 ) (3,519 ) (623 ) Balance at the end of year - 407 3,926

SHAREHOLDERS' EQUITY (DEFICIENC

SHAREHOLDERS' EQUITY (DEFICIENCY)	12 Months Ended
	Dec. 31, 2015
SHAREHOLDERS' EQUITY (DEFICIENCY)[Abstract]
SHAREHOLDERS' EQUITY (DEFICIENCY)	NOTE 10 - SHAREHOLDERS' EQUITY (DEFICIENCY) A. All the ordinary and preferred shares, options and warrants exercise prices, price per share and loss per share amounts have been adjusted retroactively for all periods presented in these financial statements, to reflect the 1 for 20 reverse stock split effected immediately prior to the consummation of the IPO on February 24, 2015 (See Note 1C). B. See Note 1D regarding the conversion on a 1:1 basis, of each and every class and series of the Company's authorized and outstanding preferred shares into the Company's Pre-Split Ordinary Shares and the conversion on a 1:1 basis of all outstanding preferred share warrants into warrants to purchase Pre-Split Ordinary Shares, each of which occurred immediately prior to the consummation of the IPO on February 24, 2015. C. Composition of preferred share capital and ordinary share capital: Authorized Issued and outstanding December 31, December 31, 2 0 1 5 2 0 1 4 2 0 1 5 2 0 1 4 Number of shares of NIS 0.2 Ordinary shares 57,500 43,358 11,812 1,152 Preferred shares Series A Preferred shares - 338 - 338 Series B Preferred shares - 338 - 338 Series C-1 Preferred shares - 875 - 821 Series C-2 Preferred shares - 1,592 - 1,489 Series C-3 Preferred shares - 1,500 - - Series D-1 Preferred shares - 4,000 - 1,227 Series D-2 Preferred shares - 3,000 - - Series D-3 Preferred shares - 2,250 - 126 Series D-4 Preferred shares - 250 - - D. Preferred shares (1) The preferred shares provide their owners with similar rights to the ordinary shares with a liquidation preference. In the occurrence of a Liquidation Event (as such term was defined in the Company's Articles of Association), the preferred shares confer upon their holders preference rights, such that each preferred share entitles its holder to be paid out of the assets of the Company available for distribution to its shareholders, an amount per preferred share equal to its original issue price, plus a yield of 8 (2) Of the warrants issued to the lead investor, warrants to purchase 41,822 4.99 50,399 5.38 the IPO these warrants were classified as a liability in accordance with ASC 480 (see Note 9) (3) In consideration for brokerage services in connection with the series C preferred share investment: (i) on December 15, 2009, the Company issued warrants to purchase 18,586 5.38 8,366 5.38 (4) On March 17, 2011, the Company issued warrants to purchase 810,013 20,570 25,196 On February 24, 2015, these warrants were converted to equity and expired on March 17, 2015. (5) Immediately prior to the consummation of the IPO, on February 24, 2015, 4,338,998 4,338,998 948,000 948,000 E. Ordinary shares (1) The ordinary shares provide their owners with rights to receive dividends in cash and shares, and rights to participate at the time of distributing liquidation dividends, subject to the preferential rights of the preferred shareholders, as described below. Additionally, the ordinary shareholders have the right to vote in shareholders' assemblies in a manner that each share provides one voting right to its holder. (2) Changes in ordinary share capital Description Amount raised, gross Shares issued Price per share Warrants issued Ordinary shares on December 31, 2014 $ 59 1,152,138 - Exercise of Anti-dilution Warrants (a) - 205,599 - 390,276 Conversion to ordinary shares immediately prior to the IPO (Note 1 $ 20,197 4,338,998 - Credit Line Warrants (d) - - - 2,658,463 Exercise of options (c) $ 16 307,467 $ 0.05 Exercise of Credit Line Warrants (e) $ 29 1,557,507 $ 0.02 IPO (b) $ 13,500 2,250,000 $ 6.00 1,125,000 3,375,000 100,000 15,000 Private Placement (d) $ 12,000 2,000,000 $ 6.00 1,000,000 3,000,000 87,127 Subtotal $ 45,801 Less: Issuance expenses $ (3,849 )* December 31, 2015 $ 41,952 (*)Issuance expenses do not include certain warrants with value of $ 321 a) On May 11, 2010, the Company issued, free of charge, to all of its shareholders (except for certain ordinary shareholders), warrants to purchase an aggregate of 390,276 171,715 33,884 180,192 b) On February 24, 2015, the Company consummated an IPO in the U.S. of 2,000,000 6 one one one one one 7.50 one 6.90 The Company granted the underwriters a 45 300,000 450,000 100,000 one one one 150,000 75,000 10.8 2.9 196 c) Immediately prior to the consummation of the IPO, certain members of the Company's management exercised 307,467 d) On August 20, 2014, the Company entered into a certain credit line agreement, pursuant to which it obtained a credit line in an aggregate principal amount of $ 12 2 1 2,658,463 ten 0.2 Under the terms of the credit line agreement, the Company directed that the entire credit line amount be invested in a Private Placement, from the lenders that was deposited in escrow and consummated concurrently with the consummation of the IPO on February 24, 2015. The Company issued to the Lenders 2,000,000 6 one one one one one 7.50 one 6.90 10.9 1.2 125 Certain 70,010 5.06 two 17,117 0.2 0.05) two 0.9 e) Certain Private Placement investors exercised warrants to purchase 569,355 0.2 0.05) 988,152 24,277 f) Upon the closing of the IPO, the Company issued warrants to purchase 100,000 7.50 15,000 6 g) On June 24, 2015, the Company entered into Amendment No. 1 to the Warrant Agreement, dated June 24, 2015, between the Company and American Stock Transfer & Trust Company LLC, as Warrant Agent, to extend the Registration Due Date to the date which is 180 days following the date of closing of the Company's initial public offering (i.e., August 23, 2015) in order to allow the shareholders who were the original purchasers of IPO Units additional time to become the direct registered owners of the ordinary shares underlying the IPO Units. On August 23, 2015, 1,298,374

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2015
SHARE-BASED COMPENSATION [Abstract]
SHARE-BASED COMPENSATION	NOTE 11 - SHARE-BASED COMPENSATION A. General (1) In connection with the transfer of all of the business operations and substantially all of the assets of Check-Cap LLC to the Company in 2009, the Company assumed the Check-Cap LLC 2006 Unit Option Plan (hereafter: the "2006 Plan”). According to the 2006 Plan, the Company is authorized to grant options to purchase ordinary shares of the Company to employees, directors and consultants of the Company. The options granted according to the 2006 Plan are generally exercisable for 10 . (2) On January 15, 2015, the Board of Directors resolved to increase the number of ordinary shares by 4% of the Company's fully-diluted share capital (including the option pool) immediately following the consummation of the IPO. As a result, the number of the Company's ordinary shares reserved for issuance under the 2006 Plan increased by 967,747 (3) On April 6, 2015, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2006 Plan by 1,718,540 (4) On August 13, 2015, the shareholders approved and adopted the Check-Cap Ltd. 2015 Equity Incentive Plan (the “2015 Israeli Plan”) and the Check-Ltd. 2015 United States Sub-Plan to Check-Cap Ltd. 2015 Equity Incentive Plan (the “2015 U.S. Sub-Plan” and together with the 2015 Israeli Plan, the “2015 Plan”). As of such date, the Company ceased to grant options under the 2006 Plan. All of the remaining shares authorized but unissued under the 2006 Plan were rolled over to the 2015 Plan . B. Details of share-based grants made by the Company The following tables presents the grant dates, number of underlying shares and related prices of awards granted to employees and non-employees during the years 2015, 2014, 2013 as well as the estimated fair value of the underlying ordinary shares on the grant date : Grant date No. of options Expiration date Exercise price Fair value on grant date May 15, 2013 (1) 38,473 February 24, 2025 $ 4.96 $ 3.04 June 6, 2013 (2) 117,750 June 12, 2023 $ 4.96 $ 3.04 October 14, 2014 (3) 581,542 October 14, 2024 ( * ) $ 3.01 February 24, 2015 (6) 302,420 February 24, 2025 $ 5.06 $ 2.73 March 15, 2015 (7) 60,484 March 15, 2025 $ 5.08 $ 2.71 May 19, 2015 (8) 523,621 May 19, 2025 $ 4.57 $ 2.50 June 1, 2015 (9) 48,387 June 1, 2025 $ 5.06 $ 2.80 June 3, 2015 (10) 189,043 June 3, 2025 $ 4.35 $ 2.60 August 13, 2015 (11) 324,750 August 13, 2025 $ 3.68 $ 1.80 August 13, 2015 (12) 425,000 August 13, 2025 $ 3.68 $ 1.85 October 20, 2015 (13) 38,369 October 20, 2025 $ 2.79 $ 1.72 Grant date No. of warrants Expiration date Exercise price Fair value on grant date February 18, 2015 100,000 February 18, 2019 $ 7.50 $ 1.62 February 24, 2015 15,000 February 24, 2019 $ 6.00 $ 2.25 October 14, 2014 (4) 221,539 October 14, 2022 ( * ) $ 3.01 Various dates in 2015 (5) 87,127 Various dates in 2017 ( ** ) $ 1.43 (*) See Note 11B(3) (**) See Note 11B(6) (1) 38,473 ordinary shares issuable upon the exercise of options with an exercise price of $4.96 per ordinary share which the Company agreed that certain executive officers will be entitled to upon completion of the IPO. The compensation expense was based on the fair value on the grant date, and was estimated at approximately $ 116 (2) On June 6, 2013, the Company's Board of Directors approved the grant of options to purchase 117,750 ordinary shares, at an exercise price of $4.96, to employees and consultants of the Company. Of such options, options to purchase 16,147 67,583 two 25,688 three 8,332 four 84 (3) On October 14, 2014, the Company's Board of Directors approved the grant of options to purchase 581,542 0.2 fifty 0.2 eight 24 1.7 (4) In addition, in October 2014, the Company's Board of Directors approved the grant of warrants to purchase 221,539 0.2 0.2 no fifty 0.2 eight 24 eight ten 667 (5) Certain finders engaged by the Company were entitled, according to the terms of their respective engagements with the Company, to be issued warrants to purchase ordinary shares upon and subject to the closing of a Private Placement pursuant to the credit line agreement dated August 20, 2014, as amended. On April 6, 2015, the Company's Board of Directors approved the grant of warrants to purchase 70,010 5.06 17,117 0.2 two (100 125 (6) On January 15, 2015, the Company's shareholders approved the grant of options to certain members of the Company's Board of Directors to purchase 302,420 ordinary shares, at an exercise price equal to the effective price per share of the ordinary shares underlying the units sold to the public in the IPO. Following the IPO the effective exercise price was determined at$5.06 per share. The options shall vest over a period of three 826 (7) On April 6, 2015, the Company's shareholders approved the grant of options to purchase 60,484 ordinary shares, at an exercise price of $5.08, to a member of the Company's Board of Directors. The options shall vest over a period of three 164 (8) On May 19, 2015 the Company's shareholders approved the grant of options to purchase 463,137 4.57 four 25 In addition, the Company's shareholders approved the grant of options to purchase 60,484 4.57 three The compensation expense was based on the fair value on the grant date, and was estimated at approximately $ 1.3 (9) On February 12, 2015, the Company's shareholders approved the grant of options to purchase 48,387 ordinary shares, at an exercise price of $5.06, to a member of the Company's Board of Directors, in consideration for certain business development services in Asia under a consulting agreement. The options shall vest over a period of three 136 (10) On June 3, 2015, the Company's Board of directors approved the grant of options to purchase 189,043 ordinary shares, at an exercise price of $4.35, to employees and consultants of the Company The compensation expense was based on the fair value on the grant date, and was estimated at approximately $ 491 (11) On August 13, 2015 the Company's Board of Directors approved the grant of options to four 25 586 (12) On August 13, 2015 the Company's Board of Directors approved the grant of options to purchase up to 425,000 ordinary shares to its CEO at an exercise price of $3.68. The options shall vest over a period of four 425,000 8,500,000 no 106,250 12 700 (13) On October 20, 2015 the Company's Board of Directors approved the grant of options to purchase 38,369 ordinary shares to certain of the Company's employees at an exercise price of $2.79. The options shall vest over a period of four 25 58 C. Options Fair Value The parameters which were used in applying the model are as follows: Share price (in $) Exercise price (in $) Expected volatility (in %) Option term (in years) Risk free interest rate (in %) Anticipated rate of dividends (in %) May 15, 2013 3.04 4.96 55 62 5 6.5 1.47 1.79 0 June 6, 2013 3.04 4.96 40 60 5 10 0.75 2.25 0 October 14, 2014 3.01 See Note 11 (3) 50 60 5 6 1.45 1.72 0 February 18, 2015 5.06 7.50 55 4 1.36 0 February 24, 2015 5.12 6 56 4 1.29 0 February 24, 2015 5.12 5.06 55 62 5 6.5 1.47 1.79 0 March 15, 2015 5.08 5.08 55 61 5 6.5 1.59 1.92 0 May 19, 2015 4. 22 4.57 44 60 5.5 7 1.62 2.03 0 June 1, 2015 4.18 5.06 56 61 5 6.5 1.50 2.20 0 June 3, 2015 4.35 4.35 56 61 5 10 1.50 2.20 0 August 13, 2015 3.44 3.68 55 60 5.5 7 1.58 1.94 0 August 13, 2015 3.44 3.68 55 60 5.5 7 1.58 1.94 0 October 20, 2015 3.00 2.79 57 61 5 10 1.75 2.28 0 D. Effect of share-based compensation transactions on the Company's statements of operations For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Research and development, net 790 104 40 General and administrative 2,934 208 16 Total 3,724 312 56 E. A summary of the Company's option activity related to options granted to employees, service providers and directors, and related information is as follows Year ended December 31, 2015 Number of options Weighted average of exercise price (in $) Average remaining contractual life (in years) Aggregate intrinsic value ($ in thousands) Outstanding at the beginning of the year 1,299,514 2.73 7.36 1,854 Granted 1,950,547 4.28 Exercised (307,467 ) 0.05 Forfeited (169,423 ) 4.60 Outstanding at the end of the year 2,773,171 4.01 7.99 (5,878 ) Vested and expected to vest 2,768,825 4.01 7.98 (5,874 ) Exercisable at the end of the year 1,092,544 3.89 5.94 (2,180 ) Year ended December 31, 2014 Number of options Weighted average of exercise price (in $) Average remaining contractual life (in years) Aggregate intrinsic value ($ in thousands) Outstanding at the beginning of the year 771,446 3.02 5.55 510 Granted 581,542 2.56 Exercised - - Forfeited (53,474 ) 4.94 Outstanding at the end of the year 1,299,514 2.73 7.36 1,854 Vested and expected to vest 1,299,514 2.73 7.36 1,854 Exercisable at the end of the year 619,057 2.92 5.15 1,854 Year ended December 31, 2013 Number of options Weighted average of exercise price (in $) Average remaining contractual life (in years) Aggregate intrinsic value ($ in thousands) Outstanding at the beginning of the year 700,428 2.72 7.08 665 Granted 117,750 4.96 Exercised - - Forfeited (46,732 ) 3.42 Outstanding at the end of the year 771,446 3.02 5.55 510 Vested and expected to vest 771,446 3.02 5.55 510 Exercisable at the end of the year 594,916 2.84 6.01 500 The weighted average grant date fair values of options granted during the years ended December 31, 2015, 2014, 2013 were $ 2.26 3.01 3.04 The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders exercised their options on the last date of the exercise period. No option was exercised during the years ended December 31, 2013 and 2014. The total intrinsic value of options exercised for the year ended December 31, 2015 was $ 1.5 1,896 2,198 4

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES, NET	12 Months Ended
	Dec. 31, 2015
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET	NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES, NET Composition: For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Salaries and related expenses 3,585 2,425 2,178 Share-based compensation 790 104 40 Materials 608 385 307 Subcontractors 688 294 218 Depreciation 85 72 70 Cost for registration of patents 153 72 118 Others 282 123 110 6,191 3,475 3,041 Less participation of the OCS and BIRD Foundation (354 ) (643 ) (148 ) Total research and development, net 5,837 2,832 2,893

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Dec. 31, 2015
GENERAL AND ADMINISTRATIVE EXPENSES[Abstract]
GENERAL AND ADMINISTRATIVE EXPENSES	NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES Composition: For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Salaries and related expenses 1,830 952 682 Share-based compensation 2,934 208 16 Professional services 609 114 96 Office rent and maintenance 108 105 104 Depreciation 7 7 7 Others 1,138 317 185 Total general and administrative 6,626 1,703 1,090

FINANCE INCOME (EXPENSES), NET

FINANCE INCOME (EXPENSES), NET	12 Months Ended
	Dec. 31, 2015
FINANCE INCOME (EXPENSES), NET [Abstract]
FINANCE INCOME (EXPENSES), NET	NOTE 14 - FINANCE INCOME (EXPENSES), NET Composition: For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Interest income on short-term deposits 61 10 59 Bank fees and Interest expenses (47 ) (6 ) (5 ) Changes in provision for royalties (33 ) 415 (104 ) Exchange rate differences 18 (13 ) 31 Revaluation of fair value of warrants to purchase preferred share 174 3,519 623 Total financing income 173 3,925 604

LOSS PER SHARE

LOSS PER SHARE	12 Months Ended
	Dec. 31, 2015
LOSS PER SHARE [Abstract]
LOSS PER SHARE	NOTE 15 - LOSS PER SHARE Basic loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the common stock considered outstanding during the year, in accordance with ASC 260-10 "Earnings per share". All outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share for each period presented, since all such securities have an anti-dilutive effect. The following table sets forth the computation of the Company`s basic and diluted net loss per ordinary share: For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Net loss 12,290 610 3,368 Preferred shares dividend 295 1,958 1,958 Net loss attributable to ordinary shares 12,585 2,568 5,326 Shares used in computing net loss per ordinary shares, basic and diluted (in thousands) 11,918 2,181 1,627 Net loss per ordinary share, basic and diluted 1.06 1.18 3.27 Instruments that may potentially dilute the basic loss per share in the future, but were not included in the calculation of diluted loss per share, since their effect is anti-dilutive. For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 13 (number) Warrants and share options 9,535 780 650 Preferred shares 654 4,339 4,339 22,107 7,300 6,616

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2015
RELATED PARTIES [Abstract]
RELATED PARTIES	16 - RELATED PARTIES A. Compensation to the non-executive directors: For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Fees, including reimbursement of expenses 291 15 - Share-based compensation 1,264 69 - 1,555 84 - B. Transactions with related parties: For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Consulting fees, including share based compensation and reimbursement of expenses (1) 177 40 40 Key man life insurance premium (3) 11 11 9 188 51 49 1) On July 1, 2005, the Company entered into an agreement with Hadar Kimchy according to which Hadar Kimchy provides marketing communication and graphical design services to the Company in consideration for a monthly retainer of NIS 10,260 3) 13,680 4) 2) The Company engaged Mr. XiangQian (XQ) Lin, who has served as a director since February 24, 2015, to provide certain business development services in Asia under a consulting agreement entered into with him on June 1, 2015. As compensation for his services, Mr. Lin is entitled to a monthly fee of $ 10 300 48,387 5.06 3) In connection with the asset transfer agreement entered into with the Predecessor Entity in May 2009, the Company assumed the former obligation of the Predecessor Entity to distribute any proceeds it collects on the $ 1 C. Participation in the Company's IPO and concurrent Private Placement 1) IPO: As discussed in Note 10E(2)(b), on February 24, 2015, the Company closed a public offering, selling 2,000,000 6 Beneficial owner Shares purchased Series A Warrants purchased Long Term Incentive Warrants purchased Proceeds, before expenses, to the Company Pontifax Funds 125,000 62,500 187,500 $ 750 Docor International B.V. 41,666 20,833 62,499 $ 250 Esco Ventures Pte Ltd 166,667 83,333.5 250,000.5 $ 1,000 2) Private Placement As discussed in Note 10E(2)(c), on August 20, 2014, the Company entered into a certain credit line agreement, pursuant to which it obtained a credit line in an aggregate principal amount of $ 12 2,658,463 2,000,000 6 Beneficial owner CLA Warrants Shares purchased Series A Warrants purchased Long Term Incentive Warrants purchased Proceeds, before expenses, to the Company Pontifax Funds 332,337 250,001 125,000.5 375,001.5 $ 1,500 Docor International B.V. 110,769 83,334 41,667 125,001 $ 500 Counterpoint Ventures Fund II LP 56,493 42,500 21,250 63,750 $ 255

SUMMARY OF SIGNIFICANT ACCOUN24

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Use of Estimates in Preparation of Financial Statements	A. Use of Estimates in Preparation of Financial Statements T
Principles of Consolidation	B. Principles of Consolidation The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances.
Financial statements in U.S dollars	C. Financial statements in U.S dollars The Company has not yet generated revenues, and the majority of its expenses is in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other. Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management is using these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company. Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.
Cash and cash equivalents and restricted cash	D. Cash and cash equivalents and restricted cash Cash and cash equivalents includes cash in hand and short–term deposits in banks with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value. The Company had a restricted cash balance of $ 46
Short-term bank deposit	E. Short-term bank deposit Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short–term bank deposits are presented at their cost, including accrued interest, which approximates fair value. As of December 31, 2015, the Company's short–term bank deposit was in dollars and bore interest rate of 0.51
Concentration of credit risks	F. Concentration of credit risks Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents and short-term bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.
Property and equipment	G. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is using the straight-line method over the estimated useful lives of the assets at the following annual rates: Length of useful life Depreciation rate Years % Office furniture and equipment 10 - 14 7 - 10 Laboratory equipment 3 - 7 15 - 33 Computers and auxiliary equipment 3 33
Impairment of Long-Lived Assets	H. Impairment of Long-Lived Assets The Company's long-lived assets are reviewed for impairment in whenever events or changes in indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2015, 2014 and 2013, no impairment losses have been recorded.
Research and development costs	I. Research and development costs Research and development costs are expensed as incurred and consist primarily of personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor (the “OCS”) and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company will generate sales from these projects and pay the royalties resulting from such sales). See Note 12 below regarding the offset of grants received for participation in research and development expenses.
Warrants to purchase preferred shares	J. Warrants to purchase preferred shares The Company accounts for freestanding warrants to purchase its preferred shares as a liability on the balance sheets at fair value. The warrants to purchase preferred shares are recorded as a liability as they include anti-dilution protection provision requiring a reduction in original exercise price as a result of subsequent issuance below the original exercise price. The warrants are subject to re-measurement to fair value at each balance sheet date and any change in fair value is recognized as a component of financial income (expense), net, in the statements of operations. The Company must adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants, or the conversion of convertible preferred shares into ordinary shares. Immediately prior to the consummation of the Company's IPO in February 2015, all of the remaining warrants to purchase preferred shares were converted to warrants to purchase ordinary shares, without the anti-dilution protection provision and the warrants were reclassified into equity at their current fair value (see Note 9).
Fair Value Measurement	K. Fair Value Measurement Fair value is defined as the exchange price that would be received for an asset or paid to a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows: • Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities; • Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.
Contingent liabilities	L. Contingent liabilities The accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of , estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December 31, 2015 and 2014, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note 8).
Share-based compensation	M. Share-based compensation In accordance with ASC 718-10 "Compensation-Stock Compensation" the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations. The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award, net of estimated forfeitures. ASC No. 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures. The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. Prior to the Company's IPO, the fair value of the ordinary shares underlying the share options has been determined based on recent e quity investment by the Company's Board of Directors. After the IPO and until March 18, 2015, the date the units , issued by the company in the IPO, After the Unit Separation Date, the grant date fair value for share-options awards is based on the closing price of the ordinary shares on the NASDAQ Capital Market on the date of grant and fair value for all other purposes related to share-options awards is the closing price of the Company's ordinary shares on the NASDAQ Capital Market on the relevant date. The fair value for options granted in 2015, 2014 and 2013 is estimated at the date of grant using a Black-Scholes-Merton option-pricing model with the following assumptions: December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Expected volatility 44 -62 % 50 -60 % 40 -60 % Risk-free rate 1.29 -2.28 % 1.45 -1.72 % 0.75 -2.25 % Dividend yield 0 % 0 % 0 % Expected term (in years) 4 10 5 6 5 10 Share price $ 3 5.12 $ 3.01 $ 3.04 The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model.
Income taxes	N. Income taxes The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered ‘more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2015 and 2014, the Company had no unrecognized income tax positions and correspondingly there is no impact on the Company's effective income tax rate associated with these items.
New Accounting Pronouncements	O. New Accounting Pronouncements In November, 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-17, Topic 740 - Balance Sheet Classification of Deferred Taxes. The ASU requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. Netting of deferred tax assets and deferred tax liabilities by tax jurisdiction is still required under the new guidance. The Company will apply the ASU in its future financial statements. In 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which defines management's responsibility to assess an entity's ability to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016 with early adoption permitted. The Company is currently evaluating the effect, if any, that the adoption of this guidance will have on the Company's financial statements. In June 2014 the FASB issued Accounting Standards Update ("ASU") 2014-10 regarding development stage entities. The ASU removes the definition of development stage entity, as was previously defined under U.S. GAAP, from the accounting standards codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the ASU eliminates the requirements for development stage entities to (i) present inception-to-date information in the statement of income, cash flow and stockholders' equity, (ii) label the financial statements as those of a development stage entity, (iii) disclose a description of the development stage activities in which the entity is engaged, and (iv) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments' to ASU 2014-10 are effective for annual reporting periods beginning after December 15, 2014. The Company has applied the ASU in these financial statements.

SUMMARY OF SIGNIFICANT ACCOUN25

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of Depreciation Inputs	Length of useful life Depreciation rate Years % Office furniture and equipment 10 - 14 7 - 10 Laboratory equipment 3 - 7 15 - 33 Computers and auxiliary equipment 3 33
Schedule of Fair Value Assumptions	December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Expected volatility 44 -62 % 50 -60 % 40 -60 % Risk-free rate 1.29 -2.28 % 1.45 -1.72 % 0.75 -2.25 % Dividend yield 0 % 0 % 0 % Expected term (in years) 4 10 5 6 5 10 Share price $ 3 5.12 $ 3.01 $ 3.04 Share price (in $) Exercise price (in $) Expected volatility (in %) Option term (in years) Risk free interest rate (in %) Anticipated rate of dividends (in %) May 15, 2013 3.04 4.96 55 62 5 6.5 1.47 1.79 0 June 6, 2013 3.04 4.96 40 60 5 10 0.75 2.25 0 October 14, 2014 3.01 See Note 11 (3) 50 60 5 6 1.45 1.72 0 February 18, 2015 5.06 7.50 55 4 1.36 0 February 24, 2015 5.12 6 56 4 1.29 0 February 24, 2015 5.12 5.06 55 62 5 6.5 1.47 1.79 0 March 15, 2015 5.08 5.08 55 61 5 6.5 1.59 1.92 0 May 19, 2015 4. 22 4.57 44 60 5.5 7 1.62 2.03 0 June 1, 2015 4.18 5.06 56 61 5 6.5 1.50 2.20 0 June 3, 2015 4.35 4.35 56 61 5 10 1.50 2.20 0 August 13, 2015 3.44 3.68 55 60 5.5 7 1.58 1.94 0 August 13, 2015 3.44 3.68 55 60 5.5 7 1.58 1.94 0 October 20, 2015 3.00 2.79 57 61 5 10 1.75 2.28 0

PREPAID EXPENSES AND OTHER CU26

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2015
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	December 31, 2 0 1 5 2 0 1 4 Government institutions 400 46 Prepaid expenses 197 27 Deposits 55 43 Other assets 28 1 680 117

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2015
PROPERTY AND EQUIPMENT, NET [Abstract]
Schedule of Property and Equipment, Net	December 31, 2 0 1 5 2 0 1 4 Cost: Office furniture and equipment 100 92 Laboratory equipment 378 306 Computers and auxiliary equipment 396 206 874 604 Accumulated depreciation 505 413 Property and equipment, net 369 191

EMPLOYEE BENEFITS AND PAYROLL28

EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)	12 Months Ended
	Dec. 31, 2015
EMPLOYEE BENEFITS AND PAYROLL ACCRUALS [Abstract]
Schedule of Employee Benefits and Payroll Accruals	December 31, 2 0 1 5 2 0 1 4 Short-term employee benefits: Benefits for vacation and recreation pay 275 332 Liability for payroll, bonuses and wages 963 790 1,238 1,122

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
INCOME TAXES [Abstract]
Schedule of Deferred Income Taxes	December 31, 2 0 1 5 2 0 1 4 Carry forward tax losses 23,565 16,800 Less valuation allowance (23,565 ) (16,800 ) - -

COMMITMENTS AND CONTINGENT LI30

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2015
COMMITMENTS AND CONTINGENT LIABILITIES [Abstract]
Schedule of Reimbursement Liability	December 31, 2 0 1 5 2 0 1 4 Royalties to an ASIC designer 159 151 Reimbursement liability to Predecessor Entity's unit holders 418 393 577 544
Schedule of Operating Leases	Operating lease obligations as of December 31, 2015: Lease agreement for vehicles 29 Lease agreement for office facilities lease 13 42

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2015
FAIR VALUE MEASUREMENTS [Abstract]
Changes in Fair Value	December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Balance at the beginning of year 407 3,926 4,549 Conversion to warrants to purchase ordinary share immediately prior to the IPO (233 ) - - Change in fair value (174 ) (3,519 ) (623 ) Balance at the end of year - 407 3,926
Series C Preferred Stock [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Summary of Fair Value Assumptions	February 24, 2015 (conversion date) December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Expected volatility 55.69 % 51.7 % 44 % Risk-free rate 1.21 % 1.58 % 0.13 % Dividend yield 0 % 0 % 0 % Expected term (in years) 4.17 4.20 3.42
Series D Preferred Stock [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Summary of Fair Value Assumptions	December 31, 2 0 1 4 2 0 1 3 Expected volatility 60.12 % 44 % Risk-free rate 0.05 % 0.18 % Dividend yield 0 % 0 % Expected term (in years) 0.21 1.21

SHAREHOLDERS' EQUITY (DEFICIE32

SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)	12 Months Ended
	Dec. 31, 2015
SHAREHOLDERS' EQUITY (DEFICIENCY)[Abstract]
Summary of Stockholders' Equity	Authorized Issued and outstanding December 31, December 31, 2 0 1 5 2 0 1 4 2 0 1 5 2 0 1 4 Number of shares of NIS 0.2 Ordinary shares 57,500 43,358 11,812 1,152 Preferred shares Series A Preferred shares - 338 - 338 Series B Preferred shares - 338 - 338 Series C-1 Preferred shares - 875 - 821 Series C-2 Preferred shares - 1,592 - 1,489 Series C-3 Preferred shares - 1,500 - - Series D-1 Preferred shares - 4,000 - 1,227 Series D-2 Preferred shares - 3,000 - - Series D-3 Preferred shares - 2,250 - 126 Series D-4 Preferred shares - 250 - -
Summary of Ordinary Share Activity	Description Amount raised, gross Shares issued Price per share Warrants issued Ordinary shares on December 31, 2014 $ 59 1,152,138 - Exercise of Anti-dilution Warrants (a) - 205,599 - 390,276 Conversion to ordinary shares immediately prior to the IPO (Note 1 $ 20,197 4,338,998 - Credit Line Warrants (d) - - - 2,658,463 Exercise of options (c) $ 16 307,467 $ 0.05 Exercise of Credit Line Warrants (e) $ 29 1,557,507 $ 0.02 IPO (b) $ 13,500 2,250,000 $ 6.00 1,125,000 3,375,000 100,000 15,000 Private Placement (d) $ 12,000 2,000,000 $ 6.00 1,000,000 3,000,000 87,127 Subtotal $ 45,801 Less: Issuance expenses $ (3,849 )* December 31, 2015 $ 41,952

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2015
SHARE-BASED COMPENSATION [Abstract]
Summary of Awards Granted	Grant date No. of options Expiration date Exercise price Fair value on grant date May 15, 2013 (1) 38,473 February 24, 2025 $ 4.96 $ 3.04 June 6, 2013 (2) 117,750 June 12, 2023 $ 4.96 $ 3.04 October 14, 2014 (3) 581,542 October 14, 2024 ( * ) $ 3.01 February 24, 2015 (6) 302,420 February 24, 2025 $ 5.06 $ 2.73 March 15, 2015 (7) 60,484 March 15, 2025 $ 5.08 $ 2.71 May 19, 2015 (8) 523,621 May 19, 2025 $ 4.57 $ 2.50 June 1, 2015 (9) 48,387 June 1, 2025 $ 5.06 $ 2.80 June 3, 2015 (10) 189,043 June 3, 2025 $ 4.35 $ 2.60 August 13, 2015 (11) 324,750 August 13, 2025 $ 3.68 $ 1.80 August 13, 2015 (12) 425,000 August 13, 2025 $ 3.68 $ 1.85 October 20, 2015 (13) 38,369 October 20, 2025 $ 2.79 $ 1.72 Grant date No. of warrants Expiration date Exercise price Fair value on grant date February 18, 2015 100,000 February 18, 2019 $ 7.50 $ 1.62 February 24, 2015 15,000 February 24, 2019 $ 6.00 $ 2.25 October 14, 2014 (4) 221,539 October 14, 2022 ( * ) $ 3.01 Various dates in 2015 (5) 87,127 Various dates in 2017 ( ** ) $ 1.43 (*) See Note 11B(3) (**) See Note 11B(6)
Schedule of Fair Value Assumptions	December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Expected volatility 44 -62 % 50 -60 % 40 -60 % Risk-free rate 1.29 -2.28 % 1.45 -1.72 % 0.75 -2.25 % Dividend yield 0 % 0 % 0 % Expected term (in years) 4 10 5 6 5 10 Share price $ 3 5.12 $ 3.01 $ 3.04 Share price (in $) Exercise price (in $) Expected volatility (in %) Option term (in years) Risk free interest rate (in %) Anticipated rate of dividends (in %) May 15, 2013 3.04 4.96 55 62 5 6.5 1.47 1.79 0 June 6, 2013 3.04 4.96 40 60 5 10 0.75 2.25 0 October 14, 2014 3.01 See Note 11 (3) 50 60 5 6 1.45 1.72 0 February 18, 2015 5.06 7.50 55 4 1.36 0 February 24, 2015 5.12 6 56 4 1.29 0 February 24, 2015 5.12 5.06 55 62 5 6.5 1.47 1.79 0 March 15, 2015 5.08 5.08 55 61 5 6.5 1.59 1.92 0 May 19, 2015 4. 22 4.57 44 60 5.5 7 1.62 2.03 0 June 1, 2015 4.18 5.06 56 61 5 6.5 1.50 2.20 0 June 3, 2015 4.35 4.35 56 61 5 10 1.50 2.20 0 August 13, 2015 3.44 3.68 55 60 5.5 7 1.58 1.94 0 August 13, 2015 3.44 3.68 55 60 5.5 7 1.58 1.94 0 October 20, 2015 3.00 2.79 57 61 5 10 1.75 2.28 0
Schedule of Share-Based Compensation	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Research and development, net 790 104 40 General and administrative 2,934 208 16 Total 3,724 312 56
Schedule of Stock Option Activity	Year ended December 31, 2015 Number of options Weighted average of exercise price (in $) Average remaining contractual life (in years) Aggregate intrinsic value ($ in thousands) Outstanding at the beginning of the year 1,299,514 2.73 7.36 1,854 Granted 1,950,547 4.28 Exercised (307,467 ) 0.05 Forfeited (169,423 ) 4.60 Outstanding at the end of the year 2,773,171 4.01 7.99 (5,878 ) Vested and expected to vest 2,768,825 4.01 7.98 (5,874 ) Exercisable at the end of the year 1,092,544 3.89 5.94 (2,180 ) Year ended December 31, 2014 Number of options Weighted average of exercise price (in $) Average remaining contractual life (in years) Aggregate intrinsic value ($ in thousands) Outstanding at the beginning of the year 771,446 3.02 5.55 510 Granted 581,542 2.56 Exercised - - Forfeited (53,474 ) 4.94 Outstanding at the end of the year 1,299,514 2.73 7.36 1,854 Vested and expected to vest 1,299,514 2.73 7.36 1,854 Exercisable at the end of the year 619,057 2.92 5.15 1,854 Year ended December 31, 2013 Number of options Weighted average of exercise price (in $) Average remaining contractual life (in years) Aggregate intrinsic value ($ in thousands) Outstanding at the beginning of the year 700,428 2.72 7.08 665 Granted 117,750 4.96 Exercised - - Forfeited (46,732 ) 3.42 Outstanding at the end of the year 771,446 3.02 5.55 510 Vested and expected to vest 771,446 3.02 5.55 510 Exercisable at the end of the year 594,916 2.84 6.01 500

RESEARCH AND DEVELOPMENT EXPE34

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)	12 Months Ended
	Dec. 31, 2015
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]
Schedule of Research and Development Expenses, Net	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Salaries and related expenses 3,585 2,425 2,178 Share-based compensation 790 104 40 Materials 608 385 307 Subcontractors 688 294 218 Depreciation 85 72 70 Cost for registration of patents 153 72 118 Others 282 123 110 6,191 3,475 3,041 Less participation of the OCS and BIRD Foundation (354 ) (643 ) (148 ) Total research and development, net 5,837 2,832 2,893

GENERAL AND ADMINISTRATIVE EX35

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
GENERAL AND ADMINISTRATIVE EXPENSES[Abstract]
Schedule of General and Administrative Expenses	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Salaries and related expenses 1,830 952 682 Share-based compensation 2,934 208 16 Professional services 609 114 96 Office rent and maintenance 108 105 104 Depreciation 7 7 7 Others 1,138 317 185 Total general and administrative 6,626 1,703 1,090

FINANCE INCOME (EXPENSES), NET

FINANCE INCOME (EXPENSES), NET (Tables)	12 Months Ended
	Dec. 31, 2015
FINANCE INCOME (EXPENSES), NET [Abstract]
Schedule of Finance Income (Expense), Net	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Interest income on short-term deposits 61 10 59 Bank fees and Interest expenses (47 ) (6 ) (5 ) Changes in provision for royalties (33 ) 415 (104 ) Exchange rate differences 18 (13 ) 31 Revaluation of fair value of warrants to purchase preferred share 174 3,519 623 Total financing income 173 3,925 604

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2015
LOSS PER SHARE [Abstract]
Schedule of Loss Per Share	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Net loss 12,290 610 3,368 Preferred shares dividend 295 1,958 1,958 Net loss attributable to ordinary shares 12,585 2,568 5,326 Shares used in computing net loss per ordinary shares, basic and diluted (in thousands) 11,918 2,181 1,627 Net loss per ordinary share, basic and diluted 1.06 1.18 3.27
Schedule of Anti-Dilutive Securities	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 13 (number) Warrants and share options 9,535 780 650 Preferred shares 654 4,339 4,339 22,107 7,300 6,616

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	12 Months Ended
	Dec. 31, 2015
Compensation to the Non-Executive Directors [Member]
Related Party Transaction [Line Items]
Schedule of Related Party Transactions	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Fees, including reimbursement of expenses 291 15 - Share-based compensation 1,264 69 - 1,555 84 -
Transactions with Related Parties [Member]
Related Party Transaction [Line Items]
Schedule of Related Party Transactions	For the year ended December 31, 2 0 1 5 2 0 1 4 2 0 1 3 Consulting fees, including share based compensation and reimbursement of expenses (1) 177 40 40 Key man life insurance premium (3) 11 11 9 188 51 49 1) On July 1, 2005, the Company entered into an agreement with Hadar Kimchy according to which Hadar Kimchy provides marketing communication and graphical design services to the Company in consideration for a monthly retainer of NIS 10,260 3) 13,680 4) 2) The Company engaged Mr. XiangQian (XQ) Lin, who has served as a director since February 24, 2015, to provide certain business development services in Asia under a consulting agreement entered into with him on June 1, 2015. As compensation for his services, Mr. Lin is entitled to a monthly fee of $ 10 300 48,387 5.06 3) In connection with the asset transfer agreement entered into with the Predecessor Entity in May 2009, the Company assumed the former obligation of the Predecessor Entity to distribute any proceeds it collects on the $ 1
IPO [Member]
Related Party Transaction [Line Items]
Schedule of Related Party Transactions	Beneficial owner Shares purchased Series A Warrants purchased Long Term Incentive Warrants purchased Proceeds, before expenses, to the Company Pontifax Funds 125,000 62,500 187,500 $ 750 Docor International B.V. 41,666 20,833 62,499 $ 250 Esco Ventures Pte Ltd 166,667 83,333.5 250,000.5 $ 1,000
Private Placement [Member]
Related Party Transaction [Line Items]
Schedule of Related Party Transactions	Beneficial owner CLA Warrants Shares purchased Series A Warrants purchased Long Term Incentive Warrants purchased Proceeds, before expenses, to the Company Pontifax Funds 332,337 250,001 125,000.5 375,001.5 $ 1,500 Docor International B.V. 110,769 83,334 41,667 125,001 $ 500 Counterpoint Ventures Fund II LP 56,493 42,500 21,250 63,750 $ 255

GENERAL INFORMATION (Details)

GENERAL INFORMATION (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015₪ / shares	Dec. 31, 2014₪ / shares
GENERAL INFORMATION [Abstract]
Net loss | $	$ 12,290	$ 610	$ 3,368
Accumulated deficit | $	$ 34,115	$ 21,825
Reverse stock split	0.05
Conversion of Stock [Line Items]
Ordinary shares, par value | ₪ / shares				₪ 0.2	₪ 0.2
Preferred Shares Conversion [Member]
Conversion of Stock [Line Items]
Number of shares converted	4,338,998
Number of shares issued for conversion	4,338,998
Preferred Share Warrants Conversion [Member]
Conversion of Stock [Line Items]
Number of shares converted	948,000
Number of shares issued for conversion	948,000

SUMMARY OF SIGNIFICANT ACCOUN40

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Line Items]
Restricted cash	$ 46	$ 46
Short-term bank deposit, interest rate	0.51%
Options [Member]
Black-Scholes-Merton option-pricing model assumptions:
Expected volatility, minimum	44.00%	50.00%	40.00%
Expected volatility, maximum	62.00%	60.00%	60.00%
Risk-free rate, minimum	1.29%	1.45%	0.75%
Risk-free rate, maximum	2.28%	1.72%	(2.25%)
Dividend yield	0.00%	0.00%	0.00%
Share price		$ 3.01	$ 3.04
Options [Member] | Minimum [Member]
Black-Scholes-Merton option-pricing model assumptions:
Expected term	4 years	5 years	5 years
Share price	$ 3
Options [Member] | Maximum [Member]
Black-Scholes-Merton option-pricing model assumptions:
Expected term	10 years	6 years	10 years
Share price	$ 5.12
Office furniture and equipment [Member] | Minimum [Member]
Accounting Policies [Line Items]
Length of useful life	10 years
Depreciation rate	7.00%
Office furniture and equipment [Member] | Maximum [Member]
Accounting Policies [Line Items]
Length of useful life	14 years
Depreciation rate	10.00%
Laboratory equipment [Member] | Minimum [Member]
Accounting Policies [Line Items]
Length of useful life	3 years
Depreciation rate	15.00%
Laboratory equipment [Member] | Maximum [Member]
Accounting Policies [Line Items]
Length of useful life	7 years
Depreciation rate	33.00%
Computers and auxiliary equipment [Member]
Accounting Policies [Line Items]
Length of useful life	3 years
Depreciation rate	33.00%

PREPAID EXPENSES AND OTHER CU41

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]
Government institutions	$ 400	$ 46
Prepaid expenses	197	27
Deposits	55	43
Other assets	28	1
Prepaid expenses and other current assets	$ 680	$ 117

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation expenses	$ 92	$ 78	$ 77
Property and equipment	874	604
Accumulated depreciation	505	413
Property and equipment, net	369	191
Office furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	100	92
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	378	306
Computers and auxiliary equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 396	$ 206

SHORT TERM LOANS (Details)

SHORT TERM LOANS (Details) - Bank Leumi Credit Facility [Member] $ in Thousands	2 Months Ended
	Mar. 16, 2015USD ($)
Line of Credit Facility [Line Items]
Borrowing capacity	$ 1,000
Amount drawn	1,000
Facility fee	20
Collateral	$ 100
LIBOR [Member]
Line of Credit Facility [Line Items]
Basis spread	5.25%

EMPLOYEE BENEFITS AND PAYROLL44

EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
EMPLOYEE BENEFITS AND PAYROLL ACCRUALS [Abstract]
Benefits for vacation and recreation pay	$ 275	$ 332
Liability for payroll, bonuses and wages	963	790
Employee benefits and payroll accruals	$ 1,238	$ 1,122

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Deferred income taxes
Carry forward tax losses	$ 23,565	$ 16,800
Less valuation allowance	$ (23,565)	$ (16,800)
Deferred income taxes
Income tax rate	26.50%	26.50%
Tax rate in 2016 and thereafter	25.00%
Foreign maximum tax rate	39.00%
Company [Member]
Operating Loss Carryforwards [Line Items]
NOL	$ 23,600
Check-Cap U.S. Inc [Member]
Operating Loss Carryforwards [Line Items]
NOL	$ 11

COMMITMENTS AND CONTINGENT LI46

COMMITMENTS AND CONTINGENT LIABILITIES (Details)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015EUR (€)
Future payments:
Operating lease obligations	$ 42,000
Royalties:
Royalties provision	577,000	$ 544,000
Funding	354,000	643,000	$ 148,000
ASIC designer [Member]
Royalties:
Royalties payable per unit sold	(540)			€ 500
Maximum royalties payable	(218,000)			€ 200,000
Royalties provision	159,000	151,000
Reimbursement liability to Predecessor Entity's unit holders [Member]
Royalties:
Royalties provision	418,000	393,000
OCS [Member]
Royalties:
Funding	3,600,000
Contingent liability	3,800,000
BIRD Foundation [Member]
Royalties:
Maximum royalties payable	900,000
Funding	$ 127,000
Royalty repayment, percentage of products sold	5.00%			5.00%
Minimum [Member]
Leases:
Term	32 months
Minimum [Member] | OCS [Member]
Royalties:
Royalty repayment, percentage of products sold	3.00%			3.00%
Maximum [Member]
Leases:
Term	36 months
Maximum [Member] | OCS [Member]
Royalties:
Royalty repayment, percentage of products sold	5.00%			5.00%
Office facilities [Member]
Leases:
Term	10 years
Rent expense	$ 67,000	$ 60,000	$ 56,000
Future payments:
Operating lease obligations	13,000
Vehicles [Member]
Future payments:
2,016	131,000
2,017	98,000
2,018	16,000
Monthly lease expense	14,000
Operating lease obligations	$ 29,000

FAIR VALUE MEASUREMENTS (Summar

FAIR VALUE MEASUREMENTS (Summary of Fair Value Assumptions) (Details) - shares	2 Months Ended	12 Months Ended
	Feb. 24, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Series C Preferred Share Warrants Conversion [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of shares issued for conversion		92,221
C2 Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expired		8,366	18,586
C2 Warrants [Member] | Series C Preferred Share Warrants Conversion [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of shares converted		50,399
C1 Warrants [Member] | Series C Preferred Share Warrants Conversion [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Number of shares converted		41,822
Warrants, Series C Preferred Shares [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected volatility	55.69%		51.70%	44.00%
Risk-free rate	1.21%		1.58%	0.13%
Dividend yield	0.00%		0.00%	0.00%
Expected term	4 years 2 months 1 day		4 years 2 months 12 days	3 years 5 months 1 day
Warrants, Series D Preferred Shares [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected volatility			60.12%	44.00%
Risk-free rate			0.05%	0.18%
Dividend yield			0.00%	0.00%
Expected term			2 months 16 days	1 year 2 months 16 days

FAIR VALUE MEASUREMENTS (Change

FAIR VALUE MEASUREMENTS (Changes in Fair Value) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
FAIR VALUE MEASUREMENTS [Abstract]
Balance at the beginning of year	$ 407	$ 3,926	$ 4,549
Conversion to warrants to purchase ordinary share immediately prior to the IPO	(233)
Change in fair value	$ (174)	$ (3,519)	$ (623)
Balance at the end of year		$ 407	$ 3,926

SHAREHOLDERS' EQUITY (DEFICIE49

SHAREHOLDERS' EQUITY (DEFICIENCY) (Schedule of Capital Composition) (Details)	12 Months Ended
	Dec. 31, 2015₪ / sharesshares	Dec. 31, 2014₪ / sharesshares
Class of Stock [Line Items]
Reverse stock split	0.05
Ordinary shares
Par value | ₪ / shares	₪ 0.2	₪ 0.2
Authorized	57,500,000	45,357,710
Issued	11,811,709	1,152,138
Outstanding	11,811,709	1,152,138
Preferred shares
Par value | ₪ / shares	₪ 0.2	₪ 0.2
Authorized	0	12,142,291
Issued	0	4,338,998
Outstanding	0	4,338,998
Series A Preferred Stock [Member]
Preferred shares
Authorized		338,000
Issued		338,000
Outstanding		338,000
Series B Preferred Stock [Member]
Preferred shares
Authorized		338,000
Issued		338,000
Outstanding		338,000
Series C1 Preferred Stock [Member]
Preferred shares
Authorized		875,000
Issued		821,000
Outstanding		821,000
Series C2 Preferred Stock [Member]
Preferred shares
Authorized		1,592,000
Issued		1,489,000
Outstanding		1,489,000
Series C3 Preferred Stock [Member]
Preferred shares
Authorized		1,500,000
Issued
Outstanding
Series D1 Preferred Stock [Member]
Preferred shares
Authorized		4,000,000
Issued		1,227,000
Outstanding		1,227,000
Series D2 Preferred Stock [Member]
Preferred shares
Authorized		3,000,000
Issued
Outstanding
Series D3 Preferred Stock [Member]
Preferred shares
Authorized		2,250,000
Issued		126,000
Outstanding		126,000
Series D4 Preferred Stock [Member]
Preferred shares
Authorized		250,000
Issued
Outstanding

SHAREHOLDERS' EQUITY (DEFICIE50

SHAREHOLDERS' EQUITY (DEFICIENCY) (Preferred Shares) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Liquidation preference		8.00%
Preferred Shares Conversion [Member]
Class of Stock [Line Items]
Number of shares converted	4,338,998
Number of shares issued for conversion	4,338,998
Preferred Share Warrants Conversion [Member]
Class of Stock [Line Items]
Number of shares converted	948,000
Number of shares issued for conversion	948,000
Series C1 Preferred Stock [Member] | Investor Warrants [Member]
Class of Stock [Line Items]
Shares called by warrants		41,822
Exercise price		$ 4.99
Series C2 Preferred Stock [Member]
Class of Stock [Line Items]
Exercise price	$ 5.38
Expiration of warrants	8,366
Series C2 Preferred Stock [Member] | Investor Warrants [Member]
Class of Stock [Line Items]
Shares called by warrants		50,399
Exercise price		$ 5.38
Series C2 Preferred Stock [Member] | Services Warrants [Member]
Class of Stock [Line Items]
Exercise price		$ 5.38
Expiration of warrants		18,586
Series D1 Preferred Stock [Member] | Services Warrants [Member]
Class of Stock [Line Items]
Expiration of warrants	25,196
Series D2 Preferred Stock [Member] | Investor Warrants [Member]
Class of Stock [Line Items]
Expiration of warrants	810,013
Series D2 Preferred Stock [Member] | Services Warrants [Member]
Class of Stock [Line Items]
Expiration of warrants	20,570

SHAREHOLDERS' EQUITY (DEFICIE51

SHAREHOLDERS' EQUITY (DEFICIENCY) (Ordinary Shares) (Details)	2 Months Ended	10 Months Ended	12 Months Ended
	Feb. 24, 2015USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares	Dec. 31, 2013USD ($)shares	Dec. 31, 2015₪ / shares
Class of Stock [Line Items]
Share capital | $	$ 59,000		$ 59,000
Conversion of preferred shares into ordinary shares | $			20,197,000
Issuance of ordinary share upon exercise of stock options by employees | $			16,000
Exercise of warrants into ordinary shares | $			29,000
Subtotal | $		$ 45,801,000	45,801,000	$ 59,000
Issuance expenses | $			3,849,000
Share capital | $		$ 41,952,000	$ 41,952,000
Shares issued		11,811,709	11,811,709	1,152,138
Exercise of options			307,467
Issuance of ordinary shares in the Private Placement, shares			2,000,000
Issuance of ordinary shares in the IPO, shares			2,250,000
Price per share | $ / shares		$ 0.05	$ 0.05
Conversion of shares			4,338,998
Value or warrants | $			$ 321,000
Number of units		300,000	300,000
Issuance of ordinary shares in IPO, net of issuance expense | $			$ 10,947,000
Issuance of ordinary shares in the Private Placement, net of issuance expenses | $			$ 11,021,000
October 20 [Member]
Class of Stock [Line Items]
Warrants issued			17,117
Exercise price | (per share)		$ 0.05	$ 0.05			₪ 0.2
Expiration period			2 years
April 6 [Member]
Class of Stock [Line Items]
Warrants issued			70,010
Exercise price | $ / shares		$ 5.06	$ 5.06
Expiration period			2 years
Anti-Dilutive Warrants [Member]
Class of Stock [Line Items]
Exercise of warrants	171,715	33,884	205,599
Warrants issued			390,276
Shares called by warrants		180,192	180,192
CLA Warrants [Member]
Class of Stock [Line Items]
Exercise of warrants			1,557,507
Warrants issued			2,658,463
Share price | $ / shares		$ 0.02	$ 0.02
Exercise price | ₪ / shares						0.2
Expiration of warrants		24,277	24,277
Principal | $		$ 12,000,000	$ 12,000,000
Expiration period			10 years
Series A Warrants [Member]
Class of Stock [Line Items]
Exercise price | $ / shares		$ 7.50	$ 7.50
Long Term Incentive Warrants [Member]
Class of Stock [Line Items]
Exercise price | $ / shares		$ 6.90	$ 6.90
Expiration of warrants		1,298,374	1,298,374
IPO [Member]
Class of Stock [Line Items]
Amount raised, gross | $			$ 13,500,000
Issuance expenses | $			$ 2,945,000
Share price | $ / shares		$ 6	$ 6
Value or warrants | $			$ 196,000
Price per unit | $ / shares			$ 6
Number of units		2,000,000	2,000,000
IPO [Member] | Series A Warrants [Member]
Class of Stock [Line Items]
Warrants issued			1,125,000
IPO [Member] | Long Term Incentive Warrants [Member]
Class of Stock [Line Items]
Warrants issued			3,375,000
IPO [Member] | Underwriter Warrants [Member]
Class of Stock [Line Items]
Warrants issued			100,000
Exercise price | $ / shares		$ 7.50	$ 7.50
IPO [Member] | Legal Warrants [Member]
Class of Stock [Line Items]
Warrants issued			15,000
Exercise price | $ / shares		6	$ 6
Private Placement [Member]
Class of Stock [Line Items]
Amount raised, gross | $			$ 12,000,000
Issuance expenses | $			$ 1,225,000
Exercise of warrants			569,355
Share price | $ / shares		$ 6	$ 6
Value or warrants | $			$ 125,000
Price per unit | $ / shares			$ 6
Number of units		2,000,000	2,000,000
Exercise price | (per share)		$ 0.05	$ 0.05			₪ 0.2
Warrants exercised on a cashless basis		988,152	988,152
Private Placement [Member] | Series A Warrants [Member]
Class of Stock [Line Items]
Warrants issued			1,000,000
Exercise price | $ / shares		$ 7.50	$ 7.50
Private Placement [Member] | Long Term Incentive Warrants [Member]
Class of Stock [Line Items]
Warrants issued			3,000,000
Exercise price | $ / shares		$ 6.90	$ 6.90
Private Placement [Member] | Services Warrants [Member]
Class of Stock [Line Items]
Issuance expenses | $			$ 900
Warrants issued			87,127
Over-Allotment Option [Member]
Class of Stock [Line Items]
Warrants issued			450,000
Over-Allotment Option [Member] | Series A Warrants [Member]
Class of Stock [Line Items]
Exercise of warrants			75,000

SHARE-BASED COMPENSATION (Award

SHARE-BASED COMPENSATION (Awards) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2015₪ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares	1,950,547	581,542	117,750
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $	$ 3,849
October 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	2 years
January 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in shares available for grant | shares	967,747
April 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	2 years
Increase in shares available for grant | shares	1,718,540
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Fair value of options on grant date	$ 2.26	$ 3.01	$ 3.04
Compensation cost not yet recognized | $	$ 1,896	$ 2,198
Period for recognizing compensation cost	4 years
Intrinsic value of options exercised | $	$ 1,500
Options [Member] | May 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date			Feb. 24, 2025
Options granted | shares			38,473
Fair value of options on grant date			$ 3.04
Exercise price			$ 4.96
Compensation cost not yet recognized | $			$ 116
Options [Member] | June 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date			Jun. 12, 2023
Options granted | shares			117,750
Fair value of options on grant date			$ 3.04
Exercise price			$ 4.96
Compensation cost not yet recognized | $			$ 84
Options [Member] | June 6 [Member] | Tranche one [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares			16,147
Options [Member] | June 6 [Member] | Tranche two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares			67,583
Vesting period			2 years
Options [Member] | June 6 [Member] | Tranche three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares			25,688
Vesting period			3 years
Options [Member] | June 6 [Member] | Tranche four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares			8,332
Vesting period			4 years
Options [Member] | October 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date		Oct. 14, 2024
Options granted | shares		581,542
Fair value of options on grant date		$ 3.01
Exercise price		$ 0.2
Compensation cost not yet recognized | $		$ 1,700
Vesting period		24 months
Options [Member] | February 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 7.50
Options [Member] | February 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$ 6
Options [Member] | February 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Feb. 24, 2025
Options granted | shares	302,420
Fair value of options on grant date	$ 2.73
Exercise price	$ 5.06
Compensation cost not yet recognized | $	$ 826
Vesting period	3 years
Options [Member] | March 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Mar. 15, 2025
Options granted | shares	60,484
Fair value of options on grant date	$ 2.71
Exercise price	$ 5.08
Compensation cost not yet recognized | $	$ 164
Vesting period	3 years
Options [Member] | March 15 [Member] | Tranche one [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares	463,137
Exercise price	$ 4.57
Vesting period	4 years
Vesting percentage	25.00%
Options [Member] | May 19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	May 19, 2025
Options granted | shares	523,621
Fair value of options on grant date	$ 2.50
Exercise price	$ 4.57
Compensation cost not yet recognized | $	$ 1,300
Options [Member] | May 19 [Member] | Tranche two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted | shares	60,484
Exercise price	$ 4.57
Vesting period	3 years
Options [Member] | June 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Jun. 1, 2025
Options granted | shares	48,387
Fair value of options on grant date	$ 2.80
Exercise price	$ 5.06
Compensation cost not yet recognized | $	$ 136
Vesting period	3 years
Options [Member] | June 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Jun. 3, 2025
Options granted | shares	189,043
Fair value of options on grant date	$ 2.60
Exercise price	$ 4.35
Compensation cost not yet recognized | $	$ 491
Options [Member] | August 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Aug. 13, 2025
Options granted | shares	324,750
Fair value of options on grant date	$ 1.80
Exercise price	$ 3.68
Compensation cost not yet recognized | $	$ 586
Vesting period	4 years
Options [Member] | August 13 [Member] | Tranche one [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Options [Member] | August 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Aug. 13, 2025
Options granted | shares	425,000
Fair value of options on grant date	$ 1.85
Exercise price	$ 3.68
Compensation cost not yet recognized | $	$ 700
Vesting period	4 years
Options [Member] | October 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Oct. 20, 2025
Options granted | shares	38,369
Fair value of options on grant date	$ 1.72
Exercise price	$ 2.79
Compensation cost not yet recognized | $	$ 58
Vesting period	4 years
Options [Member] | October 20 [Member] | Tranche one [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	25.00%
Warrants [Member] | October 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date		Oct. 14, 2022
Expiration period		8 years
Warrants granted | shares		221,539
Fair value of warrants on grant date		$ 3.01
Exercise price		$ 0.2
Compensation cost not yet recognized | $		$ 667
Vesting period		24 months
Warrants [Member] | February 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Feb. 18, 2019
Warrants granted | shares	100,000
Fair value of warrants on grant date	$ 1.62
Exercise price	$ 7.50
Warrants [Member] | February 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration date	Feb. 24, 2019
Warrants granted | shares	15,000
Fair value of warrants on grant date	$ 2.25
Exercise price	$ 6
Warrants [Member] | October 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants granted | shares	17,117
Exercise price | ₪ / shares				₪ 0.2
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | $	$ 125
Warrants [Member] | Various Dates [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants granted | shares	87,127
Fair value of warrants on grant date	$ 1.43
Warrants [Member] | April 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants granted | shares	70,010
Exercise price	$ 5.06

SHARE-BASED COMPENSATION (Fair

SHARE-BASED COMPENSATION (Fair Value Assumptions) (Details) - Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price		$ 3.01	$ 3.04
Expected volatility, minimum	44.00%	50.00%	40.00%
Expected volatility, maximum	62.00%	60.00%	60.00%
Risk-free rate, minimum	1.29%	1.45%	0.75%
Risk-free rate, maximum	2.28%	1.72%	(2.25%)
Anticipated rate of dividends	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 3
Expected term	4 years	5 years	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 5.12
Expected term	10 years	6 years	10 years
May 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price			$ 3.04
Exercise price			$ 4.96
Expected volatility, minimum			55.00%
Expected volatility, maximum			62.00%
Risk-free rate, minimum			1.47%
Risk-free rate, maximum			1.79%
Anticipated rate of dividends			0.00%
May 15 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term			5 years
May 15 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term			6 years 6 months
June 6 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price			$ 3.04
Exercise price			$ 4.96
Expected volatility, minimum			40.00%
Expected volatility, maximum			60.00%
Risk-free rate, minimum			0.75%
Risk-free rate, maximum			2.25%
Anticipated rate of dividends			0.00%
June 6 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term			5 years
June 6 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term			10 years
October 14 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price		$ 3.01
Exercise price		$ 0.2
Expected volatility, minimum		50.00%
Expected volatility, maximum		60.00%
Risk-free rate, minimum		1.45%
Risk-free rate, maximum		1.72%
Anticipated rate of dividends		0.00%
October 14 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		5 years
October 14 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term		6 years
February 18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 5.06
Exercise price	$ 7.50
Expected volatility	55.00%
Expected term	4 years
Risk-free rate	1.36%
Anticipated rate of dividends	0.00%
February 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 5.12
Exercise price	$ 6
Expected volatility	56.00%
Expected term	4 years
Risk-free rate	1.29%
Anticipated rate of dividends	0.00%
February 24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 5.12
Exercise price	$ 5.06
Expected volatility, minimum	55.00%
Expected volatility, maximum	62.00%
Risk-free rate, minimum	1.47%
Risk-free rate, maximum	1.79%
Anticipated rate of dividends	0.00%
February 24 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years
February 24 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 6 months
March 15 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 5.08
Exercise price	$ 5.08
Expected volatility, minimum	55.00%
Expected volatility, maximum	61.00%
Risk-free rate, minimum	1.59%
Risk-free rate, maximum	1.92%
Anticipated rate of dividends	0.00%
March 15 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years
March 15 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 6 months
May 19 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 4.22
Exercise price	$ 4.57
Expected volatility, minimum	44.00%
Expected volatility, maximum	60.00%
Risk-free rate, minimum	1.62%
Risk-free rate, maximum	2.03%
Anticipated rate of dividends	0.00%
May 19 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years 6 months
May 19 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	7 years
June 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 4.18
Exercise price	$ 5.06
Expected volatility, minimum	56.00%
Expected volatility, maximum	61.00%
Risk-free rate, minimum	1.50%
Risk-free rate, maximum	2.20%
Anticipated rate of dividends	0.00%
June 1 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years
June 1 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years 6 months
June 3 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 4.35
Exercise price	$ 4.35
Expected volatility, minimum	56.00%
Expected volatility, maximum	61.00%
Risk-free rate, minimum	1.50%
Risk-free rate, maximum	2.20%
Anticipated rate of dividends	0.00%
June 3 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years
June 3 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	10 years
August 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 3.44
Exercise price	$ 3.68
Expected volatility, minimum	55.00%
Expected volatility, maximum	60.00%
Risk-free rate, minimum	1.58%
Risk-free rate, maximum	1.94%
Anticipated rate of dividends	0.00%
August 13 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years 6 months
August 13 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	7 years
August 13 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 3.44
Exercise price	$ 3.68
Expected volatility, minimum	55.00%
Expected volatility, maximum	60.00%
Risk-free rate, minimum	1.58%
Risk-free rate, maximum	1.94%
Anticipated rate of dividends	0.00%
August 13 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years 6 months
August 13 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	7 years
October 20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price	$ 3
Exercise price	$ 2.79
Expected volatility, minimum	57.00%
Expected volatility, maximum	61.00%
Risk-free rate, minimum	1.75%
Risk-free rate, maximum	2.28%
Anticipated rate of dividends	0.00%
October 20 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	5 years
October 20 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	10 years

SHARE-BASED COMPENSATION (Compe

SHARE-BASED COMPENSATION (Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	$ 3,724	$ 312	$ 56
Research and development, net [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	790	104	40
General and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	$ 2,934	$ 208	$ 16

SHARE-BASED COMPENSATION (Optio

SHARE-BASED COMPENSATION (Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of options
Outstanding at the beginning of the year	1,299,514	771,446	700,428
Granted	1,950,547	581,542	117,750
Exercised	(307,467)
Forfeited	(169,423)	(53,474)	(46,732)
Outstanding at the end of the year	2,773,171	1,299,514	771,446	700,428
Vested and expected to vest	2,768,825	1,299,514	771,446
Exercisable at the end of the year	1,092,544	619,057	594,916
Weighted average of exercise price
Outstanding at the beginning of the year	$ 2.73	$ 3.02	$ 2.72
Granted	4.28	$ 2.56	$ 4.96
Exercised	0.05
Forfeited	4.60	$ 4.94	$ 3.42
Outstanding at the end of the year	4.01	2.73	3.02	$ 2.72
Vested and expected to vest	4.01	2.73	3.02
Exercisable at the end of the year	$ 3.89	$ 2.92	$ 2.84
Average remaining contractual life
Outstanding	7 years 11 months 26 days	7 years 4 months 10 days	5 years 6 months 18 days	7 years 29 days
Vested and expected to vest	7 years 11 months 23 days	7 years 4 months 10 days	5 years 6 months 18 days
Exercisable	5 years 11 months 8 days	5 years 1 month 24 days	6 years 4 days
Aggregate intrinsic value
Outstanding	$ (5,878)	$ 1,854	$ 510	$ 665
Vested and expected to vest	(5,874)	1,854	510
Exercisable	$ (2,180)	$ 1,854	$ 500

RESEARCH AND DEVELOPMENT EXPE56

RESEARCH AND DEVELOPMENT EXPENSES, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Research and Development Expenses [Line Items]
Share-based compensation	$ 3,724	$ 312	$ 56
Research and development	6,191	3,475	3,041
Less participation of the OCS and BIRD Foundation	(354)	(643)	(148)
Total research and development	5,837	2,832	2,893
Research and Development Expense [Member]
Research and Development Expenses [Line Items]
Salaries and related expenses	3,585	2,425	2,178
Share-based compensation	790	104	40
Materials	608	385	307
Subcontractors and consultants	688	294	218
Depreciation	85	72	70
Cost for registration of patent	153	72	118
Others	$ 282	$ 123	$ 110

GENERAL AND ADMINISTRATIVE EX57

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
General and Administrative Expenses [Line Items]
Share-based compensation	$ 3,724	$ 312	$ 56
Total general and administrative	6,626	1,703	1,090
General and Administrative Expense [Member]
General and Administrative Expenses [Line Items]
Salaries and related expenses	1,830	952	682
Share-based compensation	2,934	208	16
Professional services	609	114	96
Office rent and maintenance	108	105	104
Depreciation	7	7	7
Others	$ 1,138	$ 317	$ 185

FINANCE INCOME (EXPENSES), NE58

FINANCE INCOME (EXPENSES), NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
FINANCE INCOME (EXPENSES), NET [Abstract]
Interest income on short-term deposits	$ 61	$ 10	$ 59
Bank fees and Interest expenses	(47)	(6)	(5)
Changes in provision for royalties	(33)	415	(104)
Exchange rate differences	18	(13)	31
Revaluation of fair value of warrants to purchase preferred share	174	3,519	623
Total financing income	$ 173	$ 3,925	$ 604

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Basic and diluted net loss per ordinary share:
Net loss	$ 12,290	$ 610	$ 3,368
Preferred shares dividend	295	1,958	1,958
Net loss attributable to ordinary shares	$ 12,585	$ 2,568	$ 5,326
Shares used in computing net loss per ordinary shares, basic and diluted (in thousands)	11,918	2,181	1,627
Net loss per ordinary share, basic and diluted	$ 1.06	$ 1.18	$ 3.27
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive instruments	22,107	7,300	6,616
Warrant and Share Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive instruments	9,535	780	650
Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive instruments	654	4,339	4,339

RELATED PARTIES (Transactions w

RELATED PARTIES (Transactions with Related Parties) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015ILS (₪)shares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares	Dec. 31, 2013ILS (₪)shares
Related Party Transaction [Line Items]
Transactions with related parties	$ 188		$ 51	$ 49
Options granted | shares	1,950,547	1,950,547	581,542	117,750	117,750
Exercise price | $ / shares	$ 4.28		$ 2.56	$ 4.96
Sigalit Kimchy [Member]
Related Party Transaction [Line Items]
Monthly retainer	$ (4)	₪ 13,680		$ (3)	₪ 10,260
Mr. XQ Lin [Member]
Related Party Transaction [Line Items]
Hourly fee, up to five hours per month	10
Hourly fee, exceeding five hours per month	$ 300
Options granted | shares	48,387	48,387
Exercise price | $ / shares	$ 5.06
Yoav Kimchy [Member]
Related Party Transaction [Line Items]
Key man insurance policy	$ 1,000
Non-Executive Directors [Member]
Related Party Transaction [Line Items]
Transactions with related parties	1,555		$ 84
Consulting fees, including share-based compensation and reimbursement of expenses [Member]
Related Party Transaction [Line Items]
Transactions with related parties	177		40	$ 40
Key man life insurance premium [Member]
Related Party Transaction [Line Items]
Transactions with related parties	11		11	$ 9
Fees and Reimbursement [Member] | Non-Executive Directors [Member]
Related Party Transaction [Line Items]
Transactions with related parties	291		15
Share-Based Compensation [Member] | Non-Executive Directors [Member]
Related Party Transaction [Line Items]
Transactions with related parties	$ 1,264		$ 69

RELATED PARTIES (Participation

RELATED PARTIES (Participation in the Company's IPO and Concurrent Private Placement) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Related Party Transaction [Line Items]
Shares	2,250,000
Number of units	300,000
CLA Warrants [Member]
Related Party Transaction [Line Items]
Warrants	2,658,463
Principal | $	$ 12,000
IPO [Member]
Related Party Transaction [Line Items]
Number of units	2,000,000
Price per unit | $ / shares	$ 6
IPO [Member] | Pontifax Funds [Member]
Related Party Transaction [Line Items]
Shares	125,000
Proceeds, before expenses | $	$ 750
IPO [Member] | Pontifax Funds [Member] | Series A Warrants [Member]
Related Party Transaction [Line Items]
Warrants	62,500
IPO [Member] | Pontifax Funds [Member] | Long Term Incentive Warrants [Member]
Related Party Transaction [Line Items]
Warrants	187,500
IPO [Member] | Docor International B.V. [Member]
Related Party Transaction [Line Items]
Shares	41,666
Proceeds, before expenses | $	$ 250
IPO [Member] | Docor International B.V. [Member] | Series A Warrants [Member]
Related Party Transaction [Line Items]
Warrants	20,833
IPO [Member] | Docor International B.V. [Member] | Long Term Incentive Warrants [Member]
Related Party Transaction [Line Items]
Warrants	62,499
IPO [Member] | Esco Ventures Pte Ltd [Member]
Related Party Transaction [Line Items]
Shares	166,667
Proceeds, before expenses | $	$ 1,000
IPO [Member] | Esco Ventures Pte Ltd [Member] | Series A Warrants [Member]
Related Party Transaction [Line Items]
Warrants	83,333.5
IPO [Member] | Esco Ventures Pte Ltd [Member] | Long Term Incentive Warrants [Member]
Related Party Transaction [Line Items]
Warrants	250,000.5
Private Placement [Member]
Related Party Transaction [Line Items]
Number of units	2,000,000
Price per unit | $ / shares	$ 6
Private Placement [Member] | Pontifax Funds [Member]
Related Party Transaction [Line Items]
Shares	250,001
Proceeds, before expenses | $	$ 1,500
Private Placement [Member] | Pontifax Funds [Member] | CLA Warrants [Member]
Related Party Transaction [Line Items]
Warrants	332,337
Private Placement [Member] | Pontifax Funds [Member] | Series A Warrants [Member]
Related Party Transaction [Line Items]
Warrants	125,000.5
Private Placement [Member] | Pontifax Funds [Member] | Long Term Incentive Warrants [Member]
Related Party Transaction [Line Items]
Warrants	375,001.5
Private Placement [Member] | Docor International B.V. [Member]
Related Party Transaction [Line Items]
Shares	83,334
Proceeds, before expenses | $	$ 500
Private Placement [Member] | Docor International B.V. [Member] | CLA Warrants [Member]
Related Party Transaction [Line Items]
Warrants	110,769
Private Placement [Member] | Docor International B.V. [Member] | Series A Warrants [Member]
Related Party Transaction [Line Items]
Warrants	41,667
Private Placement [Member] | Docor International B.V. [Member] | Long Term Incentive Warrants [Member]
Related Party Transaction [Line Items]
Warrants	125,001
Private Placement [Member] | Counterpoint Ventures Fund II LP [Member]
Related Party Transaction [Line Items]
Shares	42,500
Proceeds, before expenses | $	$ 255
Private Placement [Member] | Counterpoint Ventures Fund II LP [Member] | CLA Warrants [Member]
Related Party Transaction [Line Items]
Warrants	56,493
Private Placement [Member] | Counterpoint Ventures Fund II LP [Member] | Series A Warrants [Member]
Related Party Transaction [Line Items]
Warrants	21,250
Private Placement [Member] | Counterpoint Ventures Fund II LP [Member] | Long Term Incentive Warrants [Member]
Related Party Transaction [Line Items]
Warrants	63,750